Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17509 | 0.80 | SMN1; SMN2 (0.56) | ALDH1A1PKMSMN1; SMN2MAPTPOLB | |
| SCHEMBL29483829 | 0.80 | SMN1; SMN2 (0.56) | ALDH1A1PKMSMN1; SMN2MAPTPOLB | |
| SCHEMBL29977958 | 0.78 | SMN1; SMN2 (0.59) | ALDH1A1PKMSMN1; SMN2MAPTPOLB | |
| SCHEMBL2633979 | 0.78 | KDM4E (0.59) | ALDH1A1PKMSMN1; SMN2MAPTPOLB | |
| SCHEMBL1256644 | 0.78 | SMN1; SMN2 (0.59) | ALDH1A1PKMSMN1; SMN2MAPTPOLB | |
| SCHEMBL4804922 | 0.78 | KDM4E (0.59) | ALDH1A1PKMSMN1; SMN2MAPTPOLB | |
| SCHEMBL19055 | 0.78 | SMN1; SMN2 (0.55) | ALDH1A1PKMSMN1; SMN2MAPTPOLB | |
| SCHEMBL4804914 | 0.78 | SMN1; SMN2 (0.59) | ALDH1A1PKMSMN1; SMN2MAPTPOLB | |
| Hydrochloric Acid SCHEMBL4803286 | 0.78 | SMN1; SMN2 (0.55) | ALDH1A1PKMSMN1; SMN2MAPTPOLB | |
| SCHEMBL23904091 | 0.77 | SMN1; SMN2 (0.53) | ALDH1A1PKMSMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| CN-105377837-B | N (heteroaryl) sulfamide derivative as S100 inhibitor | 活跃生物技术有限公司 | 2017-08-04 | — | — | CN | claimed |
| US-20250275959-A1 | COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2025-09-04 | — | — | US | disclosed |
| CN-115605467-B | PHD inhibitor compounds, compositions and uses thereof | 阿克比治疗有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120004851-A | PHD inhibitor compounds, compositions and uses thereof | 阿克比治疗有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240368189-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | VERTEX PHARMA (US) | 2024-11-07 | — | — | US | disclosed |
| CN-118852135-A | N-acyl sulfonamide compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-10-29 | — | — | CN | disclosed |
| US-20240327452-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | ENANTA PHARM INC (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | disclosed |
| US-11958879-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2002036173-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-1104760-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-0999856-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | Du Pont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| CN-1239895-A | Radiopharmaceuticals for imaging sites of infection and inflammation | DU PONT MERCK PHARMA (US) | 1999-12-29 | — | — | CN | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
| WO-1998003485-A1 | PHENOXYPROPANOLAMINES HAVING β3-ADRENERGIC ANTAGONIST ACTIVITY | SANOFI (FR) | 1998-01-29 | — | — | WO | disclosed |
| US-4273706-A | Nondiffusible heterocyclylazonaphthol dye-releasing compounds | EASTMAN KODAK COMPANY (US) | 1981-06-16 | — | — | US | disclosed |
| US-4207104-A | DIFFUSION TRANSFER TO FORM METALLIZED DYE IMAGE OF EXCELLENT STABILITY | EASTMAN KODAK COMPANY (US) | 1980-06-10 | — | — | US | disclosed |
| US-4204870-A | METALLIZED DYES | EASTMAN KODAK COMPANY (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958879-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | ALDH1A1 2488/4885PKM 3563/4885SMN1; SMN2 4504/4885 |
| US-20240368189-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | CFTR, SLC26A4, ABCB11 | ALDH1A1 1912/4885PKM 1465/4885SMN1; SMN2 4761/4885 |
| US-20240327452-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | GPBAR1, NR1H4, SLC10A1 | ALDH1A1 2488/4885PKM 3563/4885SMN1; SMN2 4504/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | ALDH1A1 1900/4885PKM 4247/4885SMN1; SMN2 2394/4885 |
| US-20250275959-A1 | COMPOUNDS AND METHODS OF THEIR USE | ACSL5, ACSL3, ACSL6 | ALDH1A1 1002/4885PKM 578/4885SMN1; SMN2 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.